Kornimate/medical-research-clean huggingface dataset:
photobiomodulation in the masseter and temporal in patients with temporomandibular joint dysfunction

Conditions: Temporomandibular Disorder

Summary: background: according to the international association for the study of pain (iasp), the term temporomandibular disorder (tmd) regards a subgroup of orofacial pain, the symptoms of which include pain or discomfort in the temporomandibular joint, ears, masticatory muscles and neck on one or both sides as well as joint sounds, limited mandibular movements or mandibular deviation and difficulties chewing. phototherapy, such as low level laser therapy (lllt) and light-emitting diode (led) therapy, is one of the resources used to treatment muscle pain. thus, there is a need to investigate therapeutic resources that combine different wavelengths as well as different light sources (lllt and led) in the same apparatus. question: the aim of the proposed study is to evaluate the effects of phototherapy on pain, activity of the masticatory muscles (masseter and anterior temporal bilaterally) and joint mobility in individuals with temporomandibular disorder (tmd). a further aim is to determine the cumulative effect 24 and 48 hours after a six session. methods/design: a placebo-controlled, double-blind, randomized, clinical trial will be carried out involving 30 women between 18 and 40 years of age with a diagnosis of myogenous tmd. the participants will then be randomly allocated to two groups totaling 15 individuals per group. group 1 submitted to a session of phototherapy with 39,27 joules per point one group will receive placebo therapy (0 joules). the following assessment tools will be administered on four separate occasions (baseline and immediately after, 24 h after and 48 h after phototherapy). pain intensity will be assessed using the visual analog scale for pain, meter for range of movement, and electromyographic emg analysis on the masseter and anterior temporal muscles. discussion: the study will support the practice of evidence-based to the use of phototherapy in individuals with a myogenous tmd. data will be published after the study is completed.


Eligibility criteria:
inclusion criteria: * all volunteers will have a diagnosis of myogenous tmd based on the rdc/tmd with moderate to severe pain in the masseter and temporal muscles rated by an expert dentist. to standardize the sample, the body mass index of all participants must be less than 25 kg/m2, as the amount of adipose tissue between the electrode and surface of the muscle can affect that reading of the electromyographic (emg) signal. all volunteers must also have an initial pain score greater than 3 points on the vas. exclusion criteria: * the exclusion criteria will be missing teeth, the use of dentures, systemic or neuromuscular diseases, a history of trauma to the face or temporomandibular joint, history of temporomandibular joint luxation, currently undergoing orthodontic treatment, or currently undergoing medicinal treatment that can affect the musculoskeletal system (analgesic, anti-inflammatory agent or muscle relaxant).
opportunistic pk/pd trial in critically ill children (optic)

Conditions: Cardiac Disease; Critically Ill; Children, Adult

Summary: optic is a prospective, open-label, non-randomized study of multiple medications administered to approximately 2000 children in the pediatric cardiac intensive care unit (pcicu) per routine clinical car by their treating provider. the purpose of this study is to characterize the pk of drugs routinely administered to children per standard of care using opportunistic and scavenged samples. the prescribing of drugs to children will not be part of this protocol. after the child/adult (\<21 years of age) is consented/enrolled, demographic and clinical data will be extracted from the ehr. biospecimen information (including date and time of sample collection) will be collected. data analysis will be conducted on all participants with at least 2 evaluable samples. the protocol represents minimal risk to the children/adults who provide body fluid for this study, including potential loss of confidentiality (samples will be assigned a unique accession number) and risks associated with blood draws. adverse events (aes)/serious adverse events (saes) caused by the study specimen collections will be monitored and recorded in the electronic data capture (edc) system.


Eligibility criteria:
inclusion criteria: to be eligible for enrollment, a potential participant must meet all the following criteria: 1. participant is \<21 years old on admission 2. participant is admitted to the pediatric cardiac intensive care unit 3. parent/legal guardian/adult participant can understand the consent process and is willing to provide informed consent/assent 4. participant is receiving one or more of the study drugs of interest at the time of enrollment exclusion criteria: 1. any condition which would make the participant, in the opinion of the investigator, unsuitable for the study
evaluating the efficacy of a video based intervention to educate teen moms about fetal alcohol syndrome (fas)

Conditions: Fetal Alcohol Syndrome; Teen Pregnancy

Summary: evaluating the efficacy of a video about fas to determine whether it has an impact on knowledge about fas and their likelihood to participate in risk taking behavior.

teenage mothers are asked to participate in the study and then randomized into an intervention or control group. both groups take a multiple choice survey and then are randomized to either watch a video about fas or not. after the video (or not for the controls) they then take a post video short answer survey. the survey results are then scored and statistical analysis performed to determine whether the video intervention increased their knowledge about fas and their likelihood to drink alcohol during pregnancy.

Eligibility criteria:
inclusion criteria: * pregnant teens aged 12 to 16 years exclusion criteria:

Keywords: fetal alcohol syndrome teen pregnancy
lymph node pathologic grading strategy

Conditions: Lung Adenocarcinoma

Summary: the percentage of high-grade patterns in metastatic lns (mlns) that can predict poor outcomes has yet to be determined. additionally, the potential implications of other histologic patterns in metastatic lymph nodes on patient outcomes warrant further investigation. we conducted a retrospective cohort study to investigate the prognostic value of pathologic pattern in metastatic lymph nodes.


Eligibility criteria:
inclusion criteria: from january 2011 to september 2021, we consecutively collected patients with invasive luad who underwent surgical resection at the department of thoracic surgery, fudan university shanghai cancer center. exclusion criteria: 1. adenocarcinoma in situ, minimally invasive adenocarcinoma, invasive mucinous adenocarcinoma, and other variants of adenocarcinoma; 2. incomplete common driver mutation data; 3. unavailable pathologic slides.
pharmacovigilance for acts in africa

Conditions: Malaria

Summary: this is a phase iv open label study assessing the safety and effectiveness of artemisinin derivatives-based combination therapy (act) when used on a large scale and under "real life" conditions.

the study will be conducted in a well defined population in burkina faso by setting up a population-based monitoring system. the monitoring for adverse events (aes) will use two approaches (active and passive) based on a repeat survey of the study population. the active surveillance population will be weekly and actively visited at home at day 7, day 14 and day 28 after drug administration. the passive surveillance population will be encouraged to report passively any ae/adr and they will not be actively visited at home. in addition, the possible exposure to acts of all the pregnant women identified during the repeat surveys in both the active and passive surveillance areas will be extracted from the drug exposure log book or elicited by history, and the data will be entered into a pregnancy register. for the effectiveness study, patients with a microscopically confirmed diagnosis of malaria (any parasite density), clinical symptoms and a blood sample for thick and thin blood smears, and later pcr analysis (on filter paper) for genotyping will be collected before antimalarial treatment, at day 28 after treatment and at any unscheduled visit. this will be repeated for each confirmed malaria episode.

Eligibility criteria:
inclusion criteria: * males and females living in nanoro dss catchment area; * signed (or thumb-printed whenever patients are illiterate) informed consent. * patients' willingness and ability to comply with the study protocol for the duration of the study. exclusion criteria: * severe malaria. * danger signs: not able to drink or breast-feed, vomiting (\> twice in 24hours), recent history of convulsions (\>1 in 24h), unconscious state, unable to sit or stand.

Keywords: malria, act, safety, efficacy, pregarnancy
efficacy of two probiotic preparations in children with acute diarrhoea

Conditions: Gastroenteritis

Summary: the purpose of this study is to determine which of two different preparations of probiotics is effective in the treatment of acute viral diarrhoea in children.

children and infants, aged 1 month to 5 years, with acute diarrhoea, will be randomised to receive either saccharomyces boulardii, a combination probiotic (lactobacillus acidophilus, lactobacillus casei, lactobacillus rhamnosus, lactobacillus plantarum, bifidobacterium infantis, streptococcus thermophillus) or placebo, to determine if one shortens the duration of diarrhoea.

Eligibility criteria:
inclusion criteria: * clinical diagnosis of acute viral gastroenteritis exclusion criteria: * moderate or severe dehydration * malnutrition * immunodeficiencies * sepsis or bacterial infection * previous use of antibiotics, antidiarrheal drugs, or probiotics, in the last four weeks. * hospitalisation * no phone number * illiteracy

Keywords: gastroenteritis diarrhea
transcriptomic profile of endometrium in different histological dating of natural cycle

Conditions: Infertility, Female

Summary: at present, the evaluation criterion of endometrial receptivity is controversial. the development of a molecular diagnostic tool, the endometrial receptivity array (era) for diagnosis of endometrial receptivity . but use of this test in patients with rif has shown that the window of implantation (woi) is displaced in only a quarter of these patients and use of a personalized embryo transfer (pet) on the day designated by era improves reproductive performance with higher cost .what is known to the others'population? the morphological changes observed on histology for each specific day after ovulation were described by noyes and his colleagues in 1950 . an endometrial biopsy that shows a difference of more than 2 days between the histologic dating and actual day after ovulation is considered to be ''out of phase''. but such pet studies according to the noyes criterion are lacking . the aim of this study is to explore the transcriptomic profile of endometrial receptivity in different histological dating of natural cycle and its clinical application.


Eligibility criteria:
inclusion criteria: * the inclusion criteria for rif group were: unexplained repeated implantation failure (rif) is defined as the absence of a gestational sac on ultrasound at 5 or more weeks after embryo transfer (et) after 3 embryo transfers with high quality embryos or after the transfer of ≥10 embryos in multiple transfers. the inclusion criteria for control group were: (1) age \<35 years; (2) regular menstrual cycles of 24-35 days; (3) baseline follicle- stimulating hormone (fsh) \< 9.0 iu/l; (4) endometrial thickness ≥8.0 mm on the day of hcg administration. exclusion criteria: * (1) uterine abnormalities (double uterus, bicornuate uterus, unicornuate uterus); (2) intrauterine adhesions（moderate - severe）, endometriosis, adenomyosis, untreated hydrosalpinx, uterine fibroids (submucosal fibroids, nonmucosal fibroids \>4.0 cm and/or endometrial pressure) (3) history of adverse pregnancy (including spontaneous abortion, stillbirth, and fetal malformation).
effects of perioperative administration of intravenous lidocaine in children operated on for acute generalized peritonitis

Conditions: Postoperative Pain

Summary: intravenous administration of lidocaine perioperatively after laparotomy for peritonitis could be an interesting alternative by reducing the duration of postoperative ileus, the intensity of pain and the patient's hospital stay, as well as the cost of management in our context of lack of financial, technical and human resources, hence the present study.


Eligibility criteria:
inclusion criteria: * all patients aged 6 to 15, classified according to the american society of anaesthesiologists (asa) (i, ii and iii) admitted for peritonitis and whose parents have given informed consent exclusion criteria: * state of shock * severe renal insufficiency (creatinine clearance less than 30 ml/min) * history of allergy to lidocaine * refusal to participate in the study

Keywords: peritonitis postoperative pain lidocaine burkina faso
vitamin d and painful diabetic neuropathy

Conditions: Painful Diabetic Neuropathy

Summary: the main objective of this study is to evaluate the effect of vitamin d3 on diabetic individual with painful neuropathy in a tertiary healthcare. the people with diabetes (type 1 and type 2) who have a douleur neuropathique 4 (dn4) score ≥4 will be considered eligible in this prospective study. their serum samples will be subjected to pre-and post-biochemical screening of serum 25 (oh) d and hba1c. the individual having vitamin d insufficiency and deficiency will be administered a single dose of oral vitamin d3 (soft gel capsule 200,000 iu), and follow-up for post-biochemical screening after 3 months.

painful diabetic neuropathy (pdn) is the most common diabetic complication in patients who have had diabetes mellitus for a long time. diabetic peripheral neuropathy is the common cause of neuropathy globally. about 50-60% of individuals with long-term diabetes develop diabetic neuropathy. several recent observational studies in diabetic individuals have provided a correlation between vitamin d insufficiency and diabetes. despite the fact that the pathogenesis of diabetic neuropathy is complex, recent investigations revealed that deficiency of vitamin d is an important factor in the development of diabetic neuropathy. also, vitamin d supplementation was found to be effective in treating neuropathic pain and preventing neuronal degeneration. aims and objectives: the assessment of the effect of single-dose, oral vitamin d in patients with painful diabetic neuropathy. materials and methods: study drug: oral cholecalciferol (vitamin d3 capsule 200,000 iu). a single oral dose of 200000 iu vitamin d will be administered in people with diabetic neuropathy, and the effect will be observed after 3 months. * sample size = 216 type 1 and 2 diabetic subjects * recruitment time = 4 months * treatment duration = 3 months ethical approval: the ethical approval for this study will be taken from the institutional review board (irb) of baqai institute of diabetology and endocrinology (bide) study area and duration: this study is going to be conducted from october 2021 to march 2022 in the outpatient department (opd) of bide. data analysis and statistics: the primary analysis will compare the change from baseline. comparisons within each treatment group across time will also be considered. the analysis will be performed with the statistical package for the social sciences (spss). assessment during the treatment period: * change from baseline in dn4 * change from baseline in serum 25 (oh) d, * change from baseline in hba1c

Eligibility criteria:
inclusion criteria: * insulin dependent diabetes * insulin independent diabetes * age range between 25 to 80 years * glycated hemoglobin (hba1c) level must be ≥ 6.5% * apparently no symptoms of vitamin d deficiency exclusion criteria: * history of hyperparathyroidism * pregnant women * lactating mothers * history for rickets and osteomalacia * on vitamin d supplementation * on multivitamin * on anti-epileptics * on steroids * on bisphosphonates * on oral contraceptives * subjects who refuse to participate in the study
efficacy and safety of subcutaneous immunotherapy in birch pollen allergic patients

Conditions: Allergy

Summary: to compare versus placebo the efficacy and safety of recombinant bet v1, natural purified bet v1 and birch pollen licenced extract used for subcutaneous immunotherapy.


Eligibility criteria:
inclusion criteria: * patients aged 18-50 with seasonal rhinoconjunctivitis for at least 2 years, and/or mild asthma range 1 and 2 gina. * positive history of birch pollen allergy (clinical history, positive skin prick test, birch specific ige, presence of birch pollen) * compliant patients * written consent. exclusion criteria: * perennial rhinoconjunctivitis and/or asthma due to cosensitization with: animal danders, mites, alternaria cladosporium * uncontrolled seasonal asthma : severe asthma permanent or not range 3 and 4 of gina. * patients treated with beta-blockers or under continuous oral corticosteroids. * pregnant women

Keywords: immunotherapy, major allergen, birch
infective keratitis in minia governate

Conditions: Infective Keratitis

Summary: the purpose of the study is to determine the microbiological aetiology, epidemiological factors, and clinical profile and treatment outcomes of infective keratitis in ophthalmology department, minia university. egypt

prospective, non-randomized, observational clinical series of cases, including 150 patients clinically diagnosed as infective corneal ulcer, attending the ophthalmology department - faculty of medicine. minia university, minia, egypt. from 2018 to 2020. detailed history taking and all clinical findings were collected. corneal scrapings were obtained from patients and subjected to staining and culture for bacterial and fungal pathogens; bacterial and fungal growth were identified by standard laboratory procedures.

Eligibility criteria:
inclusion criteria: * clinically diagnosed as infective corneal ulcer, attending the ophthalmology department - faculty of medicine - minia university, minia, egypt exclusion criteria: * healed keratitis

Keywords: infective keratitis bacterial keratitis fungal keratitis
automatic oxygen administration after major abdominal and thoracic surgery

Conditions: Major Thoracic and Abdominal Surgery

Summary: the aim of the study is to assess the use feasibility of the freeo2 system so as to deliver automatically oxygen in the post anesthesia care unit in a patient population admitted for major abdominal and thoracic surgery. the investigators' hypothesis is that freeo2 system will provide a better control of the oxygen saturation and reduce postoperative hypoxaemia.


Eligibility criteria:
inclusion criteria: * preoperative anesthetic visit for major thoracic or abdominal surgery ( ariscat risk score ≥ 26) with general anesthesia * patient consent randomization criteria: * admission in post-anesthesia care unit after major thoracic or abdominal surgery * randomization and device establishment within a time less than one hour after the endotracheal intubation * availability of the prototype freeo2 * absence of criteria of gravity justifying immediately a different technique of ventilatory support: * disturbance of consciousness with a glasgow coma score ≤ 12 * serious ventricular rhythm disorders * hemodynamic instability (sbp \<80mmhg or recourse to vasopressors) * cardiac or respiratory arrest * ph \ 55 mm hg * necessity of an oxygen flow less than 15 l / min to maintain a spo2 higher than 92%. * absence of necessity of a urgent surgery * oxygen saturation measured by spo2 sensor exclusion criteria: * bmi ≥ 35 kg/m2 * obstructive sleep apnea (with or without mechanical therapy) * emergency surgery for life-threatening * age \<18 years * pregnant women, lactating * perturbed or non-cooperative patient
cohort project of patients with inflammatory rheumatism

Conditions: Rheumatoid Arthritis; Spondyloarthritis, Axial; Psoriatic Arthritis

Summary: chronic inflammatory rheumatism (cir) is a group of inflammatory diseases that affect the joints and spine and are related to an abnormal immune response. cir includes many different forms of arthritis that manifest as painful and swollen joints, stiffness, especially in the morning and persisting even after exercise, and limited joint mobility. cir can also affect bones, cartilage, ligaments, tendons and muscles. some may affect other organs. these symptoms can lead to a reduced quality of life, limited physical activity and progressive structural and functional deterioration of the joints. current treatment for cir is aimed at reducing inflammation and relieving pain. anti-inflammatory medications such as corticosteroids and non-steroidal anti-inflammatory drugs can be used to relieve pain and inflammation. biotherapies can also be used to modify the progression of the disease. on the other hand, regular exercise can help strengthen the muscles that support the affected joints and improve mobility. physical therapies, such as physical and occupational therapy, can also help improve mobility and relieve pain. although there is no definitive cure for cir early and appropriate treatment can help reduce symptoms and improve quality of life, as well as avoid the risk of developing complications such as lung, cardiovascular, kidney, ophthalmic, liver and other diseases. it is in this context, in order to better understand cir to improve the global management of patients, and to analyze the evolution of cir over time in relation to the different treatments proposed, that the interest in creating a database of patients with cir arises.


Eligibility criteria:
inclusion criteria: * patient over 18 years of age. * patients with rheumatoid arthritis meeting acr/eular criteria or axial and/or peripheral spondyloarthritis meeting asas criteria. * patients who have failed or are intolerant of dmards (methotrexate or arava) for rheumatoid arthritis. * patients who have failed treatment with at least two nsaids for spondyloarthritis. * patients who require biologic/synthetic therapy or patients already receiving biologic or synthetic therapy. exclusion criteria: - patient under curatorship.